There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Grifols SA (GRFS – Research Report) and Elevance Health (ELV – Research Report) with bullish sentiments.
Grifols SA (GRFS)
Kepler Capital analyst Pablo de Renteria maintained a Buy rating on Grifols SA on April 20 and set a price target of EUR17.50. The company’s shares closed last Friday at $7.57.
According to TipRanks.com, Renteria is ranked #7775 out of 8380 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Grifols SA with a $18.02 average price target, representing a 141.2% upside. In a report issued on April 12, Morgan Stanley also upgraded the stock to Buy with a EUR14.00 price target.
See today’s best-performing stocks on TipRanks >>
Elevance Health (ELV)
RBC Capital analyst Ben Hendrix maintained a Buy rating on Elevance Health on April 20 and set a price target of $572.00. The company’s shares closed last Friday at $450.74, close to its 52-week low of $440.02.
According to TipRanks.com, Hendrix is a 1-star analyst with an average return of
Elevance Health has an analyst consensus of Strong Buy, with a price target consensus of $570.29, representing a 25.3% upside. In a report issued on April 19, SVB Securities also maintained a Buy rating on the stock with a $543.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GRFS:
- Grifols price target lowered to EUR 10 from EUR 13.50 at Barclays
- Grifols upgraded to Overweight from Equal Weight at Morgan Stanley
- Grifols enters R&D agreement with Selagine
- Grifols assumed at Equal Weight from Overweight at Morgan Stanley
- Grifols Executive Chairman Mayer resigns for health, personal reasons
